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Cardiac hypertrophyCav3.2 T-type Ca2+ channel is required for the activation of calcineurin/NFAT signaling in cardiac
hypertrophy. We aimed to investigate how Cav3.2 and calcineurin interact. We found that Ca2+
and calmodulin modulate the Cav3.2/calcineurin interaction. Calcineurin binding to Cav3.2
decreases the enzyme’s phosphatase activity and diminishes the channel’s current density. Phenyl-
ephrine-induced hypertrophy in neonatal cardiac myocytes is reduced by a cell-permeable peptide
with the calcineurin binding site sequence. These data suggest that Cav3.2 regulates calcineurin/
NFAT pathway through both the Ca2+ inﬂux and calcineurin binding. Our ﬁndings unveiled a recipro-
cal regulation of Ca2+ signaling which contributes to our understanding of cardiac hypertrophy.
Structured summary of protein interactions:
Cav3.2 physically interacts with cn by anti tag coimmunoprecipitation (View interaction)
 2013 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Low-voltage activated (T-type) Ca2+ channels are present in var-
ious cell types and implicated in important cellular events such as
hormone secretion, gene expression, cell proliferation and differen-
tiation, and development of neuronal and cardiac diseases [1–4].
The pore-forming subunits of T-channels are encoded by three
genes: cacna1g, cacna1h and cacna1i, for the Cav3.1, Cav3.2 and
Cav3.3 subunits [5–7]. T-channels are expressed abundantly at
embryonic and neonatal stages; particularly, the Cav3.2 subunit
is downregulated after birth in rodent hearts [8,9]. Normally T-
channels are absent in normal adult cardiac myocytes; however,
T-channels are re-expressed during development of pathological
hypertrophy, post-infarction heart and after certain hormonal
stimulation [10,11]. Moreover, our previous study shows that
Cav3.2 T-channels plays an important role in the development of
pathological cardiac hypertrophy by activating calcineurin–NFAT
signaling pathway [12].
Calcineurin is a heterodimer serine/threonine phosphatase
composed of a catalytic CnA subunit and a Ca2+ sensing regulatory
subunit, CnB. When the level of intracellular Ca2+ increases, thebinding of Ca2+-bound calmodulin to calcineurin triggers the con-
formational changes of the auto-inhibitory domain, and results in
enzyme activation [13]. One of the best characterized calcineurin
substrates is NFAT. Dephosphorylation of NFAT by calcineurin in-
duces translocation of NFAT into nucleus and activates hypertro-
phic genes expression in cardiac myocytes [14]. Multiple calcium
channels including transient receptor potential channels (TRPC1,
TRPC3, and TRPC6), Cav1.2 L-channels and Cav3.2 T-channels are
known to regulate the calcineurin/NFAT-mediated signaling path-
way [12,15–19]. However, the mechanism of how cardiac myo-
cytes distinguish the ‘‘pathological’’ (signaling) Ca2+ from the
‘‘physiological’’ (contractile) Ca2+ inﬂux remains unclear.
In this study, we investigated the biochemical and functional
interactions between Cav3.2 and calcineurin. We report here that
the interaction between Cav3.2 and calcineurin is inhibitory to
both the Cav3.2 T-current and the calcineurin activity.
2. Materials and methods
2.1. Construction of plasmids
Human Cav3.2 and calcineurin Ab cDNA were ampliﬁed by PCR
and cloned to make deletion or truncation mutants. Different mu-
tant constructs were cloned into pCMV-3tag-1a (Strategen),
pcDNA4-myc-his-A (Invitrogen), pGEX-4T-1 (Invitrogen) and pEG-
FP-C3 plasmid (Promega).
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Cardiac myocytes were prepared from ventricles of new born
rats using Neonatal Cardiomyocyte Isolation System (Worthing-
ton). Isolated myocytes were treated with 5 lM of 11R-PCISVE
peptide, 11R-AAAAAE peptide (Kelowna) or vehicle for 2 h, fol-
lowed by the treatment of 10 lM PE or vehicle for 48 h. Cells were
stained with anti-a-actinin (Sigma–Aldrich) and Alexa Fluor 594-
conjugated anti-mouse IgG (Invitrogen) antibodies and observed
by ﬂuorescence Microscopy.
2.3. Immunoprecipitation and GST pull-down assays
For immunoprecipation, transfected cells were harvested and
the cell lysates were incubated with anti-FLAG antibody-conju-
gated beads (Sigma–Aldrich) at 4 C overnight with rotation. For
GST-pull down, recombinant GST–Cav3.2 fusion protein, puriﬁed
bovine calcineurin A (Millipore), recombinant calmodulin (Milli-
pore) and/or recombinant human calcineurin B (Millipore) were
incubated overnight at 4 C with rotation. GST protein complex
were pulled-down with glutathione Sepharose beads (GE Health-
care). After wash, the bound proteins were eluted with protein
sample buffer and analyzed by Western blotting assays.
2.4. Electrophysiological measurement
pEGFP-C3 and FLAG-Cav3.2, FLAG-Cav3.2-DA or FLAG-Cav3.2-9A
plasmids were cotransfected into HEK293 cells. Whole cell patch
clamp technique was conducted as described previously [12].
2.5. NFAT-luciferase reporter assay
NFAT-luciferase (pGL4.30) was co-expressed with Cav3.2 in
HEK293 cells and the NFAT luciferase activities were determined
with Dual Luciferase Reporter Assay System (Promega). Cav3.2 cal-
cium currents were induced as described previously [12].
2.6. Calcineurin activity assay
The calcineurin activity was determined with calcineurin activ-
ity assay kit (BIOMOL) according to manufacturer’s instruction.
2.7. Statistical analysis
Results are expressed as mean ± S.E.M. Student’s t-test was used
for comparison of two groups. One-way ANOVA with Turkey–Kra-
mer test was used for comparison among three or more groups.
Data were considered statistically different if P < 0.05.
For detailed information see Supplementary materials online.3. Results
3.1. Cav3.2 interacts with the calcineurin with NFAT-like binding sites
PCISVE and LTVP
Previously, we demonstrated that overexpressed Cav3.2 inter-
acts with calcineurin in HEK293 cells [12]. Since calcineurin is a
cytosolic protein, the interacting domain may be located at the
intracellular region of the channel. We overexpressed FLAG-tagged
Cav3.2 cytoplasmic domains in HEK293 cells, and found that only
the C-terminus was co-immunoprecipitated with calcineurin
(Fig. 1A). To determine the Cav3.2 binding site in calcineurin, we
co-expressed Myc-tagged calcineurin variants with Cav3.2 C-ter-
minus (FLAG-C-WT) in HEK293 cells. We found that both Cn-WT
and CnN bind to FLAG-C-WT, while the CnC and CndM did not,which suggests the NFAT-binding domain (NBD) (327–333) of cal-
cineurin is essential for Cav3.2 binding. Two calcineurin binding
motifs, PXIXIT and LXVP, have been reported [13,20–22]. We
examined and found the highly conserved PCISVE (2190–2195)
and LTVP (2261–2264) motifs at the Cav3.2 C-terminus (Supple-
mentary Table 1). To test the role of these motifs in calcineurin
binding, we overexpressed Cav3.2 C-terminus variants in HEK293
cells and conducted immunoprecipitation. CIId1 showed reduced
interaction with calcineurin when compared to CIId2 and C-WT,
while C-9A completely lost the ability to bind calcineurin
(Fig. 1C). To test whether there are other calcineurin binding sites
within Cav3.2, weintroduced mutations to full length Cav3.2.
Cav3.2-9A (PCISVE to AAAAAE and LTVP to AAAA) and Cav3.2-DA
(without the 2081–2249 region) could not bind to endogenous cal-
cineurin (Fig. 1D). To determine which motif is more important in
calcineurin binding, we conducted in vitro GST pull-down assays
with recombinant Cav3.2 C-terminal protein (GST–CM, 2173–
2277) with mutations at PCISVE and LTVP motifs (Fig. 2E). Com-
pared to wild type (CM), both CM-5A and CM-4A mutants showed
reduced calcineurin binding ability. Interestingly, more calcineurin
were pulled down by CM-4A than CM-5A (Fig. 2E). To test whether
Cav3.2/calcineurin interaction can take place in cardiac myocytes,
we conducted GST pull-down assays with mouse heart lysate.
The results showed that GST–CII but not GST–CII5A or GST can
bind to cardiac calcineurin (Supplementary Fig. 1). Our data dem-
onstrate that Cav3.2 directly interacts with calcineurin through the
PCISVE and LTVP motifs, and the PCISVE motif plays a more dom-
inant role in calcineurin binding.
3.2. The interaction between Cav3.2 and calcineurin is calcium/
calmodulin dependent
The calcineurin/NFAT interaction and calcineurin enzymatic
activity are Ca2+-, calmodulin- and calcineurin B (CnB)-dependent
[23,24]. The binding between Cav3.2 and calcineurin was enhanced
by calmodulin and 0.1 mM Ca2+, and completely abolished by
2 mM EGTA, but not changed by CnB (Fig. 2A). Next, we examined
the Ca2+-dependence at physiological range of [Ca2+]. The GST–CII/
calcineurin interaction behaved in a Ca2+-independent manner
without calmodulin. In contrast, in the presence of calmodulin,
Cav3.2/calcineurin interaction changed dose-dependently by Ca2+
(Fig. 2B and C). These results demonstrate that Cav3.2 interacts
with calcineurin in a Ca2+/calmodulin-dependent manner.
3.3. Calcineurin-binding deﬁcient Cav3.2 T-channels display larger
current densitie
We then investigated the effect of Cav3.2/calcineurin interac-
tion on Cav3.2 Ca2+ currents. We examined the current properties
of Cav3.2, Cav3.2-9A and Cav3.2-DA in HEK293 cells by whole-cell
patch-clamp technique. The current densities of both Cav3.2-9A
and Cav3.2-DA were signiﬁcant larger than that of Cav3.2
(Fig. 3A). Supplementary Fig. 2A showed the average peak current
traces of the three constructs elicited at40 mV from a holding po-
tential of 90 mV (n = 3). The peak current amplitude of Cav3.2-DA
(161.6 ± 17.2 pA/pF, n = 10) and Cav3.2-9A (133.3 ± 18.6 pA/pF,
n = 12) were signiﬁcantly larger than that of wild type Cav3.2
(83.7 ± 11.7 pA/pF, n = 16, P < 0.05). We conducted biotinylation
assay to examine whether the effect is due to the increase of
Cav3.2 on the cell surface. There is no signiﬁcant difference in the
surface channel proteins between mutant and wild type Cav3.2
(Supplementary Fig. 2B). However, we found a leftward shift in
the voltage-dependent activation curves of Cav3.2-DA and
Cav3.2-9A (Fig. 3C). The half maximal voltages (V1/2) of the activa-
tion curves in Cav3.2, Cav3.2-9A and Cav3.2-DA are 40.4 ± 0.9
(n = 17), 46.3 ± 1.6 (n = 12, P < 0.05 vs Cav3.2) and
Fig. 1. C-terminal region of Cav3.2 interacts with the NFAT binding domain of calcineurin. (A–D) Cav3.2/calcineurin interaction in HEK293 cells was analyzed by
coimmunoprecipitation assays. (A) Upper: schematic representation of Cav3.2 T-type Ca2+ channels. Lower: Interaction between endogenous calcineurin and FLAG-tagged
Cav3.2 variants. N, N-terminus. C, C-terminus. I–II, II–III, and III–IV, indicated cytoplasmic loops. FLAG, parental vector. (B) Interaction between Cav3.2 C-terminus (FLAG-C-
WT) and Myc-tagged wild type calcineurin (Cn-WT) or its deletion mutants (CnN, CnC and CndM). (C) Interaction between endogenous calcineurin and C-WT or its mutants
(CIId1, CIId2 and C-9A). (D) Interaction between endogenous calcineurin and full length Cav3.2 (WT) or calcineurin binding deﬁcient mutants (9A and DA). (E) Direct binding
between calcineurin and Cav3.2 was determined by GST pull-down assays with Myc-tagged recombinant GST-Cav3.2 fusion protein (GST–CM) and mutants (CM-4A, CM-5A
and CM-9A). The eluents of IP and GST pull-down assays were examined by Western blotting assays with antibodies against calcineurin, FLAG and Myc, respectively.
C.-H. Huang et al. / FEBS Letters 587 (2013) 1723–1730 172549.0 ± 1.5 mV (n = 13, P < 0.05 vs Cav3.2), respectively. We
hypothesized that the changes of current density and voltage-
dependent activation curve in Cav3.2 mutants were caused by
the dissociation of calcineurin. Because NFAT XIXIT peptides inhi-
bit calcineurin/NFAT binding without affecting calcineurin enzy-
matic activity [20], we co-expressed GFP–VIVIT plasmid with
Cav3.2. GFP–VIVIT reduced the binding of calcineurin to FLAG-C-
WT (Supplementary Fig. 2C), and increased the current density of
Cav3.2 by 52% (n = 15, P < 0.05 vs Cav3.2 control (n = 35), Fig. 3B
and E). GFP–VIVIT induced a leftward shift in the activation curve
of Cav3.2 (Fig. 3D). The V1/2 of the activation curve for Cav3.2 + -
VIVIT is 45.7 ± 1.4 mV (n = 14, P < 0.05 vs Cav3.2 control
(n = 17)). Interestingly, co-expression of GFP–VIVIT did not changethe current density nor the activation curves of Cav3.2-DA and
Cav3.2-9A (Fig. 3D and E). These results suggest that dissociation
of calcineurin from Cav3.2 indeed increase the current density of
Cav3.2 and induce a leftward shift of the activation curve.
3.4. Cav3.2–calcineurin interaction inhibits calcineurin activity
We next investigated the role of calcineurin/Cav3.2 interaction
on calcineurin/NFAT signaling. We measured calcineurin phospha-
tase activity in the presence of recombinant GST–CII or GST–CII5A
proteins in vitro. GST–CII effectively inhibited calcineurin activity
(P < 0.05, n = 4), while the GST–CII5A had no effect on the calcineu-
rin activity (Fig. 4A). We have shown previously that Cav3.2 win-
Fig. 2. Cav3.2–calcineurin interaction is dependent on calmodulin and calcium
concentration. Interaction between Cav3.2 and calcineurin was analyzed by GST
pull-down assays. (A) Cav3.2–calcineurin binding in the presence or absence of
calmodulin, calcineurin B (CnB), 2 mM EGTA or 1 mM CaCl2. (B) Cav3.2–calcineurin
binding with or without calmodulin at different concentration of calcium: 0, 106,
3  106, 105, 3  105, 104 and 103 M CaCl2. Protein levels were veriﬁed by
anti-calcineurin or anti-Myc antibodies. C, The quantiﬁcation result of the Cav3.2/
calcineurin binding with (d) or without (s) calmodulin (n = 3). The densities of
calcineurin were normalized with the density of GST–CII of each sample. pCa
indicates the value of log[Ca2+].
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further conﬁrm that Cav3.2/calcineurin interaction can modulate
calcineurin/NFAT signaling pathway, we co-expressed C-WT or C-
9A with Cav3.2 and measured the Ca2+-induced NFAT-luciferase
activity. We found that C-WT reduced NFAT activation (P < 0.05,
n = 4), while C-9A showed no inhibitory effect (Fig. 4B). Next, we
tested the role of Cav3.2/calcineurin binding in cardiac hypertro-phy with a cell permeable PCISVE peptide (Supplementary
Fig. 3A) [25,26]. Similar to the GST–CII and GST–CM, 11R-PCISVE
also inhibited calcineurin phosphatase activity in vitro, while the
calcineurin binding-deﬁcient peptide (11R-AAAAAE) did not (Sup-
plementary Fig. 3B). We used PE-induced cellular hypertrophy of
rat neonatal cardiac myocytes (rNCMs) as our model (Supplemen-
tary Fig. 3C). PE treatment induced a 35% increaseof cell surface
area (P < 0.05, PE. (n = 187) vs control (n = 201)). 11R-PCISVE treat-
ment prevented the hypertrophic effect of PE (n = 192) vs 11R-
PCISVE alone (n = 198)). When cells were treated with 11R-AAAAE,
PE treatment still induced a signiﬁcant increase in cell size
(P < 0.05, 11R-AAAAAE + PE (n = 215) vs 11R-AAAAAE alone
(n = 121), Fig. 4C and D). These data suggest that the calcineurin
binding motif PCISVE of Cav3.2 negatively regulates calcineurin
activity and cardiac hypertrophy.
4. Discussion
The interaction between calcineurin and NFAT has been well
studied during past decades [13]. Biochemical studies revealed
that the linker region between catalytic and auto inhibitory do-
mains of calcineurin is essential for NFAT binding [27]. Crystal
structures later identiﬁed essential residues responsible for the
interaction between calcineurin and the VXIXIT motif, which was
found in various calcineurin binding molecules [21,28]. In addition
to the major role of the VXIXIT motif, another LXVP motif locates
near the C-terminus of NFAT was also suggested as a calcineurin
binding site [13,22]. In this study, we show that calcineurin di-
rectly interacts with Cav3.2 at the PCISVE and LTVP motifs on its
C-terminus and both sites are similar to those of NFAT [13]. Most
of the reported calcineurin interacting proteins, including NFAT,
TWIK-related spinal cord K channel (TRESK), A-kinase anchoring
proteins (AKAP79/150), have a consensus PXIXIT motif [13]. The
LXVP motif was found only in a few calcineurin substrates, such
as NFAT and KSR2 [13]. In mammals, NFATs are the only known
calcineurin binding partners bearing both consensus binding sites.
Here we demonstrate that Cav3.2 is a new calcineurin interacting
molecule containing both NFAT-like motifs.
Only a small number of membrane proteins, including cardiac
Cav1.2 and Na+/Ca2+ exchanger (NCX), interact with calcineurin
[29–32]. However, unlike Cav3.2, neither Cav1.2 nor NCX binds cal-
cineurin via an NFAT-like site. The only known ion channel with
NFAT-like calcineurin binding site is TRESK [33]. By literature re-
search, we found one PSILIQ motif and one LMVP motif at the C-
terminus of Kir6.1. Kir6.1 is the pore-forming subunit of ATP-sen-
sitive K+ (KATP) channels, which has been linked to cardiac hyper-
trophy and post-infarction heart failure [34]. Calcineurin directly
dephosphorylates the PKA-mediated phosphorylation site of
Kir6.1 and attenuates KATP currents [35]. Calcineurin also binds
to the PVITID sequence of Na+/H+ exchanger 1 (NHE1), which is
involved in cardiac hypertrophy and heart failure. The high pH
membrane microenvironment generated by NHE1 enhances
calcineurin phosphatase activity and promotes the activation of
NFAT signaling during cardiac hypertrophy [36–38]. It is possible
that calcineurin regulates cardiac remodeling not only through
the activation of NFAT, but also via direct interaction to those ion
channels containing NFAT-like binding sites.
Another novel ﬁnding of our study is that Cav3.2/calcineurin
interaction reduces the channel activity. We showed that Cav3.2-
DA and Cav3.2-9A exhibited higher current density than wild type
Cav3.2. Co-expression of VIVIT also increased the current density of
Cav3.2 but not Cav3.2-DA or Cav3.2-9A. These results suggest that
VIVIT and the lack of calcineurin binding are probably acting
through similar pathways to increase Cav3.2 current amplitude.
We observed a leftward shift in the voltage-dependent activation
Fig. 3. Calcineurin-binding deﬁcient Cav3.2 T-channels display larger current densities. Calcium currents generated by overexpressed Cav3.2 and calcineurin binding deﬁcient
mutants were measured in HEK293 cells using whole cell patch clamp technique. (A) The current density–voltage plots of Cav3.2 (d), Cav3.2–9A (.) and Cav3.2-DA (j). (B)
Current density–voltage plots in the presence of GFP–VIVIT. (C) Steady-state activation and inactivation curves. (D) Steady-state activation and inactivation curves in the
presence of GFP–VIVIT. Dashed line in panel D represents the steady-state activation curve of wild type Cav3.2 shown in panel C. (E) Normalized peak current densities.
⁄P < 0.05 compared to control group. Numbers of cells for each group are shown.
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pressed with VIVIT. The inhibitory regulation of Cav3.2 by calcineu-
rin binding could be contributed by the dephosphorylation of
Cav3.2 by calcineurin, or the physical interaction, or both. Cur-
rently, we could not rule out either possibility.
We found that the interaction between Cav3.2 and calcineurin is
calcium dependent in vitro. In addition, the enhancement of the
interaction exhibited a bell shaped Ca2+-dependence. The interac-
tion is weak at pCa > 6 ([Ca2+]i < 1 lM), increases dose-depen-
dently at 4.5 < pCa < 6.0, and peaks at pCa 4.5, and then declines
at pCa < 4.5 (Fig. 2C). It is unclear whether this calcium depen-
dence of Cav3.2/calcineurin interaction occurs in vivo. Although
the intracellular Ca2+ ([Ca2+]i) is normally under lM range
(pCa > 6), local [Ca2+]i around Ca2+ channel pores can increaseacutely when the channels open. A computer modeling study that
L-type Ca2+ current increases [Ca2+]i to mM range at a distance of
25 nm from the channel pore in cardiac myocytes [39]. Another
study predicts the local [Ca2+]i is about 76–139 lM at a distance
of 10–20 nm from the channel pore after the open of a L-channel
in presynaptic neurons [40]. The distance from Cav3.1 C-terminus
to the channel pore is estimated to be less than 5 nm [41]. Since
the length of the C-terminus is similar in Cav3.1 and Cav3.2, it is
possible that the local [Ca2+]i around the calcineurin binding sites
of Cav3.2 can reach 1 mM (pCa 3.0). Therefore, the [Ca2+]i around
Cav3.2 C-terminus may raise from pCa < 6.0 to pCa > 3.0 when
the channels open. Moreover, both the phosphatase activity and
calmodulin binding ability of calcineurin are also calcium depen-
dent and peak at 4.5 < pCa < 3.0 [42], a range that Cav3.2/calcineu-
Fig. 4. Cav3.2–calcineurin interaction reduces calcineurin activity. (A) Calcineurin phosphatase activities were determined using in vitro calcineurin activity assays with GST
(CON), GST–CII (CII) or GST–CII5A (CII5A) proteins, respectively. ⁄P < 0.05 compared to control. #P < 0.05 compared to GST–CII (n = 4). (B) Cav3.2 C-terminal domain (C-WT),
binding-deﬁcient C-9A constructs (C-9A) or vehicle vector were co-expressed with full-length Cav3.2 as indicated. Cav3.2 current-induced NFAT activation were induced by
10 mM Ca2+ for 6 h, and NFAT-luciferase activity was measured by luciferase assays. ⁄P < 0.05 compared to control. #P < 0.05 compared to Cav3.2 only group (n = 4). (C)
Representative immunoﬂuorescence images of rNCMs treated with 5 lM peptides in the presence of 10 lM phenylephrine (PE) or PBS for 2 days. Myocytes were identiﬁed by
anti-a-actinin staining. Red: a-actinin. Blue: DAPI. Scale: 50 lm. (D) Cell surface area quantiﬁcation of rNCMs. ⁄P < 0.05 compared to PBS control in the same group (n = 121–
201).
Fig. 5. Hypothetical model of Cav3.2/calcineurin/NFAT signaling pathway. During cardiac hypertrophy, Cav3.2-mediated Ca2+ inﬂux activates Ca2+/CaM complex, and induces
calcineurin binding to Cav3.2 C-terminus. The binding inhibits calcineurin activity and partially reduces the Ca2+ inﬂux at lower [Ca2+]i (nM to sub-mM, light green). When the
local Ca2+ concentration exceeds a certain level (mM, dark green), calcineurin dissociates from Cav3.2 and becomes fully activated, and subsequently dephosphorylates NFAT,
leading to NFAT nuclear translocation and downstream gene activation.
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Cav3.2 is re-expressed during cardiac hypertrophy, the calcium in-
ﬂux via Cav3.2 T-channel initiates the binding of calcineurin to the
C-terminus of Cav3.2 at pCa < 6. The activity of bound calcineurin is
partial inhibited (Fig. 4A) and with more calcium inﬂux (pCa < 4.5)
the binding between calcineurin and Cav3.2 is reduced and the dis-
sociated calcineurin will reach its optimal phosphatase activity at
4.5 < pCa < 3. The activated calcineurin can then dephosphorylate
downstream substrates like NFAT.
Although the role of calcineurin/NFAT pathway in cardiac
hypertrophy is well known, it remains unclear how this pathways
is activated only by ‘‘pathological’’ but not ‘‘physiological’’ Ca2+
changes. The [Ca2+]i oscillates from nM to lM at each heart beat
in cardiac myocytes; however, this regular [Ca2+]i oscillation does
not activate the calcineurin/NFAT pathway. One hypothesis is that
Ca2+ activates calcineurin/NFAT pathway speciﬁcally through loca-
tion-dependent microdomains and macromolecular complexes in
caveolaes [43,44].Recently, Cav3.2 T-channels were shown to colo-
calize with caveolin-3 in caveolaes in adult cardiac myocytes [45].
Several studies have suggested that calcineurin may be colocalized
with caveolin-1 and caveolin-3 [44,46]. It is possible that calcineu-
rin may be regulated by Cav3.2 T-channels in microdomains like
caveolaes during cardiac hypertrophy. Our previous study demon-
strates that Cav3.2 is required for NFAT activation during cardiac
hypertrophy [12]. The inhibitory interaction between calcineurin
and Cav3.2 shown in this study ensures that the activation of calci-
neurin only takes place at high [Ca2+]i, possibly in caveolaes. As
Fig. 5 shows, calcineurin can be recruited to re-expressed Cav3.2
in hypertrophic myocytes. The phosphatase activity of calcineurin
is inhibited when [Ca2+]i is ranged from nM to sub-mM (light green
in Fig. 5). With more calcium inﬂux, the local [Ca2+]i increases to
mM range (dark green in Fig. 5) which leads to dissociation and
fully activation of calcineurin. This mechanism can prevent the cal-
cineurin/NFAT pathway from being activated by systolic Ca2+ con-
centration oscillates in physiology conditions.
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